Abstract 18269: Select Cardiac MicroRNA Are Associated With Prevalent Atrial Fibrillation and Change After AF Ablation
Introduction: Atrial fibrillation (AF) is the most common arrhythmia in the U.S and biomarkers are needed to identify individuals at risk for AF. Cardiac microRNAs (miRNA) are associated with AF and detectable in the circulation. Data are limited on how circulating levels of miRNAs relate to AF or change over time after AF ablation.
Hypothesis: We hypothesized that miRNA associated with cardiac remodeling will be related to AF and change after AF ablation.
Methods: In 211 “miRhythm” study participants (112 with AF; 99 without AF), we quantified plasma expression of 86 miRNAs associated with cardiac remodeling or disease by high-throughput quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We used qRT-PCR to examine change in plasma miRNA expression from baseline to 1-month after ablation. To evaluate the potential source of circulating miRNAs, we examined whether miRNAs detectable in plasma were also expressed in atrial tissue in a subgroup of patients undergoing cardiac surgery.
Results: The mean age of the cohort was 59 years and 58% of participants were men. 21 miRNAs differed significantly between participants with AF and those with no AF in regression models adjusting for age, sex, smoking, diabetes mellitus, heart failure, and myocardial infarction (p value ≤ 0.0006; Figure 1). Several miRNAs associated with AF, including miRs-21 and 150, regulate expression of genes implicated in AF pathogenesis. Levels of 33 miRNAs, including 14 also associated with AF, changed significantly after catheter ablation (p value ≤ 0.0006; Figure 1). All AF-related plasma miRNAs were detectable in atrial tissue and several, including miR-21 and 411 differed with respect to preoperative AF status.
Conclusion: Plasma levels of several important miRNAs associated with cardiac remodeling were related to AF and similar miRNAs changed after catheter-ablation. Our findings implicate circulating miRNAs as markers of atrial remodeling and vulnerability to AF.
Author Disclosures: R. Velagaleti: None. K. Tanriverdi: None. H. Lin: None. N. Esa: None. M. Kinno: None. D. Mandapati: None. S. Tam: None. O. Okike: None. P. Ellinor: None. J. Keaney: None. E. Benjamin: None. J. Freedman: None. D. McManus: None.
- © 2014 by American Heart Association, Inc.